Christian Gisselbrecht
Overview
Explore the profile of Christian Gisselbrecht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
6921
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gisselbrecht C, Sibon D
Br J Haematol
. 2022 Sep;
200(1):13-14.
PMID: 36120952
Treatment of relapsed/refractory diffuse large B-cell lymphoma remains a challenge with the advent of chimaeric antigen receptor CAR-T cell treatment. Whether or not eligibility criteria should replace the standard autologous...
2.
Thanarajasingam G, Minasian L, Bhatnagar V, Cavalli F, De Claro R, Dueck A, et al.
Lancet Haematol
. 2022 Apr;
9(5):e374-e384.
PMID: 35483398
Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics over the past two decades. Targeted agents, immune and cellular therapies, and...
3.
Delgado J, Papadouli I, Sarac S, Moreau A, Hovgaard D, Gisselbrecht C, et al.
Hemasphere
. 2021 Nov;
5(12):e666.
PMID: 34805769
Tafasitamab is a humanized monoclonal antibody that binds to the CD19 antigen, which is expressed in tumor cells from patients with diffuse large B-cell lymphoma (DLBCL). On June 24, 2021,...
4.
Neelapu S, Locke F, Bartlett N, Lekakis L, Reagan P, Miklos D, et al.
Blood Adv
. 2021 Sep;
5(20):4149-4155.
PMID: 34478487
The SCHOLAR-1 international retrospective study highlighted poor clinical outcomes and survival among patients with refractory large B-cell lymphoma (LBCL) treated with conventional chemotherapy. Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric...
5.
Delgado J, Voltz C, Stain M, Balkowiec-Iskra E, Mueller B, Wernsperger J, et al.
Hemasphere
. 2021 Jul;
5(8):e616.
PMID: 34291195
Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing...
6.
Delgado J, Voltz C, Stain M, Lapvetelainen T, Urach S, Lahteenvuo J, et al.
Hemasphere
. 2021 Jul;
5(7):e604.
PMID: 34235401
Crizanlizumab is a monoclonal antibody that binds to P-selectin. On October 28, 2020, a conditional marketing authorization valid through the European Union (EU) was issued for crizanlizumab for the prevention...
7.
Delgado J, Zienowicz M, van Hennik P, Moreau A, Gisselbrecht C, Enzmann H, et al.
Oncologist
. 2021 Jul;
26(11):983-987.
PMID: 34213061
Isatuximab is a monoclonal antibody that binds to the human CD38 antigen. On May 30, 2020, a marketing authorization valid through the European Union (EU) was issued for isatuximab in...
8.
Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al.
Blood
. 2021 Jan;
137(19):2646-2656.
PMID: 33512419
First-line therapy for younger patients with peripheral T-cell non-Hodgkin lymphoma (T-NHL) consists of 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide (CHOEP), consolidated by high-dose...
9.
Delgado J, Josephson F, Camarero J, Garcia-Ochoa B, Lopez-Anglada L, Prieto-Fernandez C, et al.
Oncologist
. 2021 Jan;
26(3):242-249.
PMID: 33486852
On November 5, 2020, a marketing authorization valid through the European Union (EU) was issued for acalabrutinib monotherapy or acalabrutinib in combination with obinutuzumab (AcalaObi) in adult patients with treatment-naïve...
10.
Tzogani K, Penttila K, Lahteenvuo J, Lapvetelainen T, Lopez Anglada L, Prieto C, et al.
Oncologist
. 2020 Nov;
26(1):70-76.
PMID: 33179377
On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have...